Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

CVS Health : Revenue Rises as It Pursues Aetna

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/06/2017 | 02:11pm CET
By Cara Lombardo 

Stronger pharmacy sales boosted CVS Health Corp.'s revenue in its latest quarter as the drugstore chain weighs a purchase of health insurer Aetna Inc., a move that would bolster its prescription business.

CVS's third-quarter revenue rose 3.5% to $46.2 billion, matching what analysts polled by Thomson Reuters expected.

The Wall Street Journal reported last month that the drugstore giant is in talks to buy Aetna for $66 billion, according to people familiar with the matter, following a six-month hunt for a deal partner. The move would strengthen CVS's position in negotiations with drugmakers, and analysts are likely to question company executives about the potential tie-up on a Monday earnings call.

People familiar with the discussions have said it could take until the end of the year to solidify a deal, if it happens.

In its latest quarter, sales in CVS's pharmacy-services segment increased 8.1% to $32.9 billion, driven by growth in pharmacy network claims and specialty pharmacy volume. Retail segment sales, meanwhile, slipped 2.7% to $19.6 billion, hurt by falling same-store sales.

The company also recorded $55 million in expenses related to the recent string of hurricanes, with most of it impacting the retail segment.

Overall for the quarter, CVS reported a profit of $1.3 billion, or $1.26 a share, compared with $1.5 billion, or $1.43 a share, a year ago.

Excluding one-time items, the Woonsocket, R.I.-based company earned $1.50 a share, compared with $1.64 a year ago. Analysts had expected adjusted earnings per share of $1.48 on net income of $1.5 billion.

The company also narrowed its full-year earnings guidance and raised the midpoint. It now expects adjusted earnings of $5.87 to $5.91. It previously guided a range of $5.83 to $5.93.

CVS shares, down 12% this year, rose less than 1% premarket on low volume.

Write to Cara Lombardo at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
11/16 CVS HEALTH : Makes Overdose-Reversal Drug Available Without Individual Prescript..
11/16 CVS HEALTH : Earns Perfect Score in 2018 Corporate Equality Index
11/16 CVS HEALTH : Surescripts Transforms Prescription Decision Process Between Physic..
11/15 CVS HEALTH : delivering next-day service come the new year
11/15 Bayer hires new blood to stem 'Amazon effect' in consumer health
11/15 CVS HEALTH : Delaware, CVS Health make overdose reversal drug available without ..
11/14 CVS HEALTH : Commits to Hiring 5,000 New Apprentices by 2022, Expands States Par..
11/13 CVS HEALTH : Ensuring Our Veterans Have Access to Care
11/11 CVS HEALTH : will offer overdose reversal drug naloxone without prescription
11/10 CVS HEALTH : Public Health and CVS Health Make Overdose-Reversal Drug Available ..
More news
News from SeekingAlpha
08:13a RGA Q3 2017 Letter - Amazon's Share Of E-Commerce = PayPal's Opportunity
11/17 40 Dividend Stocks Battling Into 2018
11/17 DIVIDEND CONTENDERS : 24 Increases Expected In The Next 11 Weeks
11/16 Who Is Afraid Of Big Bad Amazon?
11/16 CVS : Undervalued
Financials ($)
Sales 2017 184 B
EBIT 2017 9 954 M
Net income 2017 5 242 M
Debt 2017 24 377 M
Yield 2017 2,76%
P/E ratio 2017 14,08
P/E ratio 2018 12,18
EV / Sales 2017 0,52x
EV / Sales 2018 0,50x
Capitalization 71 598 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 84,5 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-10.43%71 598
WALGREENS BOOTS ALLIANCE-13.91%71 930
EXPRESS SCRIPTS HOLDING CO-9.96%35 081
MCKESSON CORPORATION1.20%29 630
CARDINAL HEALTH INC-20.09%18 128
AMERISOURCEBERGEN CORP.0.83%17 275